awmsg logo



efavirenz/emtricitabine/tenofovir disoproxil (Atripla®)


Reference No. 119

Publication date:
17/03/2009


Appraisal information

efavirenz/emtricitabine/tenofovir disoproxil (Atripla®) 600 mg/200 mg/245 mg film-coated tablet


Company: Bristol-Myers Squibb Pharmaceuticals Ltd/Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 27/01/2009
AWMSG meeting date: 25/02/2009
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0209
Ministerial ratification: 16/03/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Efavirenz/emtricitabine/tenofovir disoproxil (as fumarate) (Atripla®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in adults with virological suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiviral therapy for more than three months and in accordance with current BHIVA guidance. AWMSG is of the opinion that efavirenz/emtricitabine/tenofovir disoproxil (as fumarate) (Atripla®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download